Gefitinib is named as a drug or biological intervention in 4 clinical trials in our USA, China and UK trial registers, none of which are currently recruiting. Lead sponsors include Eli Lilly and Company (1), AstraZeneca (1) and Novartis Pharmaceuticals (1). Registered phases: Phase 3 and Phase 2. Conditions studied include Metastatic Non-Small Cell Lung Cancer; Non-Small Cell Lung Cancer; Advanced Solid Tumors Which Are cMET-dependent.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT02411448 | A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (ClinicalTrials.gov ↗) Metastatic Non-Small Cell Lung Cancer |
Phase 3 | Active, closed |
| NCT04143607 | ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC (ClinicalTrials.gov ↗) Locally Advanced or Metastatic NSCLC |
Phase 3 | Active, closed |
| NCT03040973 | Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone (ClinicalTrials.gov ↗) Advanced Solid Tumors Which Are cMET-dependent |
Phase 2 | Active, closed |
| NCT03944772 | Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (ClinicalTrials.gov ↗) Non-Small Cell Lung Cancer |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Metastatic Non-Small Cell Lung Cancer | 1 |
| Non-Small Cell Lung Cancer | 1 |
| Advanced Solid Tumors Which Are cMET-dependent | 1 |
| Locally Advanced or Metastatic NSCLC | 1 |
| Lead sponsor | Trials |
|---|---|
| Eli Lilly and Company | 1 |
| AstraZeneca | 1 |
| Novartis Pharmaceuticals | 1 |
| Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 1 |
| Register | Gefitinib trials |
|---|---|
| Clinical trials in USA | 3 |
| Clinical trials in China | 3 |
| Clinical trials in UK | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Gefitinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Gefitinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.